Best supportive/best standard of care

OTHER3 trials

Conditions

Prostate Cancer

Phase 2

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

CompletedNCT05114746

Novartis PharmaceuticalsProstate Cancer

Start: 2022-01-25End: 2026-04-20Updated: 2026-05-08

Phase 3

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

CompletedNCT03511664

EndocyteProstate Cancer

Start: 2018-05-29End: 2023-12-14Updated: 2025-01-13

Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Not yet recruitingNCT07795268

Norroy Bioscience Co., LTDProstate Cancer

Start: 2026-08-31End: 2029-08-31Target: 600Updated: 2026-08-31

2025-07-10

Efficacy of 177 Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis.

Journal of Clinical Oncology2025-02-104 citations

Long-term safety outcomes of 177 Lu-PSMA-617 in patients with prostate cancer.

Journal of Clinical Oncology2025-02-101 citations

Patient characteristics and overall survival with lutetium (Lu 177 ) vipivotide tetraxetan ( 177 Lu-PSMA-617): A real-world analysis of early adopters.

Journal of Clinical Oncology2025-02-10

Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial.

2024-10-0414 citations

Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial).

2024-08-0148 citations

A randomized phase I/II study of neoadjuvant treatment with 177-Lutetium-PSMA-617 with or without ipilimumab in patients with very high-risk prostate cancer who are candidates for radical prostatectomy (NEPI trial).

Journal of Clinical Oncology2024-01-296 citations

Nearly double the patients and dramatic changes over 14 years of UK MRT: Internal Dosimetry Users Group survey results from 2007 to 2021

Nuclear Medicine Communications2023-10-304 citations

2023-06-0170 citations

Tumor dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study.

Journal of Clinical Oncology2023-06-017 citations

Tolerability of lutetium-177–PSMA-617 in men with prostate cancer and baseline cytopenia.

Journal of Clinical Oncology2023-06-011 citations

Effects of [177Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION randomized trials: An exploratory analysis.

Journal of Clinical Oncology2023-06-01

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research2022-12-05195 citations

Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer

Oncology Times2022-11-15

[177Lu]Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial.

Journal of Clinical Oncology2022-06-0125 citations

Tolerability of [177Lu]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): A VISION study subgroup analysis.

Journal of Clinical Oncology2022-06-011 citations

Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study.

Journal of Clinical Oncology2022-02-1618 citations

Exposure-adjusted safety analyses of the VISION phase 3 trial of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology2022-02-161 citations

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

New England Journal of Medicine2021-06-232294 citations

Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function

Cancers2021-06-2145 citations

8 more papers not shown

Best supportive/best standard of care

Sponsors

Conditions

Phase 2

Phase 3

Related Papers